

FOR IMMEDIATE RELEASE

TSX VENTURE: HTL



HAMILTON THORNE ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

BEVERLY, MA and TORONTO, Ontario – March 1, 2011 - Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems for the regenerative medicine, developmental biology, stem cell research and fertility markets, today announced the resignation of Scott Pearson from the Company's Board of Directors. In addition, Dr. David Sable will join Hamilton Thorne's Audit Committee. Both of these changes are effective immediately.

"Mr. Pearson has been a valuable member of our Board of Directors and we are grateful for his guidance and leadership that has helped propel the Company to achieve record sales and enter into new, lucrative research markets," said Meg Spencer, Chief Executive Officer of Hamilton Thorne Ltd. "We would like to thank Mr. Pearson for his dedicated service to the company, and wish him much success with his many additional responsibilities in his new CEO role."

The Company also announced that it has granted Dr. Sable an additional 10,000 stock options to purchase in pursuant of the Company's incentive stock option plan. The options are exercisable at Cdn\$0.275 per share, vest over three years, and expire ten years from the date of grant.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)

Hamilton Thorne is a leading provider of advanced laser systems for the regenerative medicine and stem cell research markets. Hamilton Thorne's lead products, the ZILOS-tk™ and XYClone® laser systems, attach to standard inverted microscopes and operate as robotic micro-surgeons, significantly reducing time and increasing efficiency in key in-vitro fertilization, stem cell, and regenerative medical research applications. The new Staccato™ and Stiletto™ laser systems are designed to broaden the Company's markets and offer significant advantages to developmental biology, cancer research and advanced cell biology researchers.

Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, McGill University, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University, and Cambridge.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any

forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

For more information, please contact

David Wolf, President

Hamilton Thorne Ltd.

978-921-2050

ir@hamiltonthorne.com

Lisa Rivero, Director of Corporate Communications

Hamilton Thorne Ltd.

978-921-2050

ir@hamiltonthorne.com